Literature DB >> 27774611

CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.

Dana Tedesco1, Manoj Thapa1, Sanjeev Gumber2, Elizabeth J Elrod1, Khalidur Rahman3, Chris C Ibegbu1, Joseph F Magliocca4, Andrew B Adams4, Frank Anania3, Arash Grakoui1,5.   

Abstract

Persistent hepatotropic viral infections are a common etiologic agent of chronic liver disease. Unresolved infection can be attributed to nonfunctional intrahepatic CD8+ T-cell responses. In light of dampened CD8+ T-cell responses, liver disease often manifests systemically as immunoglobulin (Ig)-related syndromes due to aberrant B-cell functions. These two opposing yet coexisting phenomena implicate the potential of altered CD4+ T-cell help. Elevated CD4+ forkhead box P3-positive (Foxp3+) T cells were evident in both human liver disease and a mouse model of chemically induced liver injury despite marked activation and spontaneous IgG production by intrahepatic B cells. While this population suppressed CD8+ T-cell responses, aberrant B-cell activities were maintained due to expression of CD40 ligand on a subset of CD4+ Foxp3+ T cells. In vivo blockade of CD40 ligand attenuated B-cell abnormalities in a mouse model of liver injury. A phenotypically similar population of CD4+ Foxp3+, CD40 ligand-positive T cells was found in diseased livers explanted from patients with chronic hepatitis C infection. This population was absent in nondiseased liver tissues and peripheral blood.
CONCLUSION: Liver disease elicits alterations in the intrahepatic CD4+ T-cell compartment that suppress T-cell immunity while concomitantly promoting aberrant IgG mediated manifestations. (Hepatology 2017;65:661-677).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27774611      PMCID: PMC5258825          DOI: 10.1002/hep.28894

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.

Authors:  Sonja Hillebrandt; Hermann E Wasmuth; Ralf Weiskirchen; Claus Hellerbrand; Hildegard Keppeler; Alexa Werth; Ramin Schirin-Sokhan; Gabriele Wilkens; Andreas Geier; Johann Lorenzen; Jörg Köhl; Axel M Gressner; Siegfried Matern; Frank Lammert
Journal:  Nat Genet       Date:  2005-07-03       Impact factor: 38.330

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

3.  Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.

Authors:  Victoria M Velazquez; Luke S Uebelhoer; Manoj Thapa; Chris C Ibegbu; Cynthia Courtney; Steven E Bosinger; Joseph F Magliocca; Andrew B Adams; Allan D Kirk; Stuart J Knechtle; Daniel Kalman; Mehul S Suthar; Arash Grakoui
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

4.  CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection.

Authors:  J K Whitmire; M K Slifka; I S Grewal; R A Flavell; R Ahmed
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 6.  A brief history of T cell help to B cells.

Authors:  Shane Crotty
Journal:  Nat Rev Immunol       Date:  2015-02-13       Impact factor: 53.106

Review 7.  Cell-mediated immunity and the outcome of hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Andrew G Cawthon; Christopher M Walker
Journal:  Annu Rev Microbiol       Date:  2004       Impact factor: 15.500

8.  Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis.

Authors:  Ruth Y Lan; Chunmei Cheng; Zhe-Xiong Lian; Koichi Tsuneyama; Guo-Xiang Yang; Yuki Moritoki; Ya-Hui Chuang; Takafumi Nakamura; Shigeru Saito; Shinji Shimoda; Atsushi Tanaka; Christopher L Bowlus; Yasuo Takano; Aftab A Ansari; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

9.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

Authors:  Takahisa Miyao; Stefan Floess; Ruka Setoguchi; Hervé Luche; Hans Joerg Fehling; Herman Waldmann; Jochen Huehn; Shohei Hori
Journal:  Immunity       Date:  2012-02-09       Impact factor: 31.745

Review 10.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

View more
  6 in total

Review 1.  Environmental peer pressure: CD4+ T cell help in tolerance and transplantation.

Authors:  Dana Tedesco; Arash Grakoui
Journal:  Liver Transpl       Date:  2018-01       Impact factor: 5.799

2.  Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.

Authors:  Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui
Journal:  J Immunol       Date:  2020-04-24       Impact factor: 5.422

3.  Foxp3+ Regulatory T Cells Inhibit CCl4-Induced Liver Inflammation and Fibrosis by Regulating Tissue Cellular Immunity.

Authors:  Yoshinobu Ikeno; Daiya Ohara; Yusuke Takeuchi; Hitomi Watanabe; Gen Kondoh; Kojiro Taura; Shinji Uemoto; Keiji Hirota
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

Review 4.  Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.

Authors:  Bridget P Keenan; Lawrence Fong; Robin K Kelley
Journal:  J Immunother Cancer       Date:  2019-10-18       Impact factor: 13.751

Review 5.  Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.

Authors:  Claudia Sirbe; Gelu Simu; Iulia Szabo; Alina Grama; Tudor Lucian Pop
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

Review 6.  Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease.

Authors:  Angus Hann; Ye H Oo; M Thamara P R Perera
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.